Access to disease modifying treatments for rheumatoid arthritis patients

Abstract

TNF inhibitors seem to be promising therapeutic agents for RA. The use of these new agents will require physicians experienced in the diagnosis, treatment and assessment of RA. These physicians will need to make long term observations for efficacy and safety. Further considerations when using TNF blocking agents in this disease must include cost issues and recognition that data in subpopulations are still being acquired. It is hoped that this statement, which is based upon the best evidence available at the time of its creation and modified by expert opinion, will facilitate the optimal use of these agents for our patients with RA.